Search research articles
Contact Us
Filters
Showing results (81-90 of 94) with videos related to
Page
of 10
Sort By:
Frontiers in Immunology
|
May 8, 2023
A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells
Yang Liu, Xingxing Jie, Li Nian, et al.
The Lancet. Haematology
|
August 6, 2019
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial
Zhiling Yan, Jiang Cao, Hai Cheng, et al.
Cytotherapy
|
September 16, 2024
Comprehensive characterization of cytopenia after chimeric antigen receptor-T cell infusion in patients with relapsed or refractory multiple myeloma
Hai Cheng, Lingyan Shao, Dandan Wang, et al.
American Journal of Hematology
|
July 31, 2015
MicroRNA-181a, a potential diagnosis marker, alleviates acute graft versus host disease by regulating IFN-γ production
Wei Sang, Cong Zhang, Dianzheng Zhang, et al.
Cytotherapy
|
April 16, 2024
Complex association of body mass index and outcomes in patients with relapsed and refractory multiple myeloma treated with CAR-T cell immunotherapy
Hai Cheng, Yingjun Sun, Xiaoxue Zhang, et al.
Haematologica
|
May 26, 2018
NLRP3 regulates platelet integrin αIIbβ3 outside-in signaling, hemostasis and arterial thrombosis
Jianlin Qiao, Xiaoqing Wu, Qi Luo, et al.
International Urology and Nephrology
|
May 1, 2025
Nephrotoxicity of CAR-T therapy in patients with relapsed and refractory multiple myeloma
Zihan Chen, Yegan Chen, Jiaying Liu, et al.
Nature Communications
|
April 20, 2024
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
Ming Shi, Jiaojiao Wang, Hongming Huang, et al.
American Journal of Hematology
|
February 18, 2022
Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia
Ming Shi, Li Li, Shiyuan Wang, et al.
Clinical and Experimental Medicine
|
November 1, 2023
Long-term analysis of cellular immunity in patients with RRMM treated with CAR-T cell therapy
Hai Cheng, Shengwei Ji, Jiaojiao Wang, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 94) with videos related to
Sort By:
Page
of 10
Frontiers in Immunology
|
May 8, 2023
A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells
Yang Liu, Xingxing Jie, Li Nian, et al.
The Lancet. Haematology
|
August 6, 2019
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial
Zhiling Yan, Jiang Cao, Hai Cheng, et al.
Cytotherapy
|
September 16, 2024
Comprehensive characterization of cytopenia after chimeric antigen receptor-T cell infusion in patients with relapsed or refractory multiple myeloma
Hai Cheng, Lingyan Shao, Dandan Wang, et al.
American Journal of Hematology
|
July 31, 2015
MicroRNA-181a, a potential diagnosis marker, alleviates acute graft versus host disease by regulating IFN-γ production
Wei Sang, Cong Zhang, Dianzheng Zhang, et al.
Cytotherapy
|
April 16, 2024
Complex association of body mass index and outcomes in patients with relapsed and refractory multiple myeloma treated with CAR-T cell immunotherapy
Hai Cheng, Yingjun Sun, Xiaoxue Zhang, et al.
Haematologica
|
May 26, 2018
NLRP3 regulates platelet integrin αIIbβ3 outside-in signaling, hemostasis and arterial thrombosis
Jianlin Qiao, Xiaoqing Wu, Qi Luo, et al.
International Urology and Nephrology
|
May 1, 2025
Nephrotoxicity of CAR-T therapy in patients with relapsed and refractory multiple myeloma
Zihan Chen, Yegan Chen, Jiaying Liu, et al.
Nature Communications
|
April 20, 2024
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
Ming Shi, Jiaojiao Wang, Hongming Huang, et al.
American Journal of Hematology
|
February 18, 2022
Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia
Ming Shi, Li Li, Shiyuan Wang, et al.
Clinical and Experimental Medicine
|
November 1, 2023
Long-term analysis of cellular immunity in patients with RRMM treated with CAR-T cell therapy
Hai Cheng, Shengwei Ji, Jiaojiao Wang, et al.
Page
of 10